<DOC>
	<DOCNO>NCT02294292</DOCNO>
	<brief_summary>Cirrhotic cardiomyopathy define chronic cardiac dysfunction patient cirrhosis . It suspect specific cardiac dysfunction contributes onset complication liver disease . The purpose prospective , randomize control trial determine whether carvedilol revert cardiac dysfunction i.e . leave ventricular diastolic dysfunction secondary cirrhosis , prevent complication ( renal dysfunction , worsen cardiac function , mortality ) .</brief_summary>
	<brief_title>Therapeutic Approach Diastolic Dysfunction Chronic Liver Disease Patients Its Impact Morbidity Mortality</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Carvedilol</mesh_term>
	<criteria>Patients cirrhosis diagnose clinical , biochemical , histological ( available ) criterion plus ultrasound imaging . Age range 1860 year Cirrhosis diagnose histology clinical , laboratory USG ( UltraSonography ) finding , Upper GI bleed undergoing secondary endoscopic variceal ligation eradication varix Age &gt; 60 year Chronic renal disease Pregnancy peripartum cardiomyopathy Hypertension Coronary artery disease Valvular heart disease Sick sinus syndrome/ Pacemaker Cardiac rhythm disorder Hypothyroidism Hyperthyroidism Portal vein thrombosis Transjugular intrahepatic porto systemic shunt ( TIPS ) insertion Hepatocellular carcinoma Anemia Hb &lt; 8gm/dl female , &lt; 9 gm/dl male</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>